Literature DB >> 17855777

Radiofrequency ablation of an epicardial ventricular tachycardia through the great cardiac vein in a patient with mitro-aortic mechanical prostheses.

Jamal Najjar1, Agustín Bortone, Serge Boveda, Jean-Paul Albenque.   

Abstract

AIMS: Prior cardiac surgery limits epicardial ventricular tachycardia (VT) ablation due to epicardial adhesions formation. METHODS AND
RESULTS: We describe an epicardial VT ablation through the coronary venous system in a patient with mechanical mitro-aortic prostheses. The different possible ablation approaches and their potential limitations are discussed.
CONCLUSION: In selected patients, especially after cardiac surgery, coronary venous system approach can be considered as a safety possible approach for the ablation of some epicardial VTs.

Entities:  

Mesh:

Year:  2007        PMID: 17855777     DOI: 10.1093/europace/eum185

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

1.  Anatomical correlates relevant to ablation above the semilunar valves for the cardiac electrophysiologist: a study of 603 hearts.

Authors:  Apoor S Gami; Amit Noheria; Nirusha Lachman; William D Edwards; Paul A Friedman; Deepak Talreja; Stephen C Hammill; Thomas M Munger; Douglas L Packer; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2010-12-15       Impact factor: 1.900

2.  Percutaneous Interventricular Septal Access Guided by Subcostal Echocardiography and Fluoroscopy for Ventricular Tachycardia Ablation in a Patient with Aortic and Mitral Mechanical Valves.

Authors:  Dursun Aras; Serkan Topaloglu; Ozcan Ozeke; Firat Ozcan; Serkan Cay; Zehra Golbasi
Journal:  J Innov Card Rhythm Manag       Date:  2019-07-15

3.  Ablation of ventricular tachycardia by direct left ventricle puncture through a minithoracotomy after double valve replacement: a case report and literature review.

Authors:  Ming-Yang Gao; Li-Jun Zeng; Xue-Xun Li; Ying Tian; Pi-Xiong Su; Xin-Chun Yang; Xing-Peng Liu
Journal:  J Int Med Res       Date:  2020-01       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.